Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

RT-PCR Targeting rpoB mRNA for Drug Susceptibility Test of Mycobacterium tuberculosis in Liquid Culture

  • Jin, Hyunwoo (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan)
  • Received : 2016.10.24
  • Accepted : 2016.12.16
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The problems of tuberculosis and its drug resistance are very severe. Therefore, rapid and accurate drug susceptibility assay is required. Recently, there has been an increased understanding of the genetic mechanism of Mycobacterium tuberculosis (MTB) drug resistance as well as advancement of molecular technologies. While many gene mutations correlate well with drug resistance, many genes do not show a strong correlation with drug resistance. For this reason, the current study assessed the utility of rpoB mRNA as a target to detect live mycobacteria. In this study, RT-PCR targeting of rpoB mRNA in BCG treated with rifampin was performed. Conventional RT-PCR and real-time PCR targeting rpoB mRNA as well as 85B mRNA was performed to determine whether these two methods could distinguish between viable and non-viable MTB. The levels of rpoB and 85B mRNA detected by RT- PCR were compared in parallel with colony forming unit counts of BCG that were treated with rifampin for different periods of time. The data suggests that that even though both mRNA levels of rpoB and 85B decreased gradually when rifampin-treatment increased, the rpoB mRNA seemed to represent live bacteria better than 85B mRNA. This study clearly indicates that RT-PCR is a good method to monitor viable cell counts in the liquid culture treated with the anti-tuberculosis drug.

Keywords

References

  1. Banaiee N, Bobadilla-Del-Valle M, Bardarov S Jr, Riska PF, Small PM, Ponce-De-Leon A, Jacobs WR Jr, Hatfull GF, Sifuentes- Osornio J. Luciferase reporter mycobacteriophages for detection, identification, and antibiotic susceptibility testing of Mycobacterium tuberculosis in Mexico. J Clin Microbiol. 2001. 39: 3883-3888. https://doi.org/10.1128/JCM.39.11.3883-3888.2001
  2. Centers for Disease Control and Prevention. Extensively drugresistant tuberculosis-United States. MMWR. 2007. 56: 250-253.
  3. Cho JE, Cho SN, Cho SA. RpoB peptide derived from Mycobacterium tuberculosis is processed and presented to HLAA* 0201 restricted CD8+ T Cells via an alternate HLA-I processing pathway. Biomed Sci Lett. 2014. 20: 250-255. https://doi.org/10.15616/BSL.2014.20.4.250
  4. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis shortcourse chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med. 1990. 112: 397-406. https://doi.org/10.7326/0003-4819-76-3-112-6-397
  5. Desjardin LE, Chen Y, Perkins MD, Teixeira L, Cave MD, Eisenach KD. Comparison of the ABI 7700 System (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis. J Clin Microbiol. 1998. 36: 1964-1968.
  6. Desjardin LE, Perkins MD, Wolski K, Haun S, Teixeira L, Chen Y, Johnson JL, Ellner JJ, Dietze R, Bates J, Cave MD, Eisenach KD. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med. 1999. 160: 203-210. https://doi.org/10.1164/ajrccm.160.1.9811006
  7. Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med. 2007. 13: 295-298. https://doi.org/10.1038/nm0307-295
  8. Dye CS, Schelle P, Dolin V, Pathania, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA. 1999. 282: 677-686. https://doi.org/10.1001/jama.282.7.677
  9. Hellyer TJ, Desjardin LE, Teixeira L, Perkins MD, Cave MD, Eisenach KD. Detection of viable Mycobacterium tuberculosis by reverse transcriptase-strand displacement amplification of mRNA. J Clin Microbiol. 1999. 37: 518-523.
  10. Hellyer T, Fletcher TW, Bates JH, Stead WW, Templeton GL, Cave MD, Eisenach KD. Strand displacement amplification and the polymerase chain reaction for monitoring response to treatment in patients with pulmonary tuberculosis. J Infect Dis. 1996. 173: 934-941. https://doi.org/10.1093/infdis/173.4.934
  11. Jung D, Lee H, Park S. Mycobacterium tuberculosis DNA detection and molecular drug susceptibility test in AFB-stained sputum slides. Biomed Sci Lett. 2016. 22: 24-28. https://doi.org/10.15616/BSL.2016.22.1.24
  12. Kim SH, Park SJ, Lee HY. Changes of cytokine and chemokine mRNA expression in whole blood cells from active pulmonary tuberculosis patients after T-Cell mitogen and Mycobacterium tuberculosis specific antigen stimulation. Biomed Sci Lett. 2014. 20: 162-167. https://doi.org/10.15616/BSL.2014.20.3.162
  13. Martin G, Lazarus A. Epidemiology and diagnosis of tuberculosis. Recognition of at-risk patients is key to prompt detection. Postgrad Med. 2000. 108: 42-54. https://doi.org/10.3810/pgm.2000.08.1179
  14. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HS, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Munoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008. 359: 563-574. https://doi.org/10.1056/NEJMoa0800106
  15. Palomino JC. Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr Opin Pulm Med. 2006. 12: 172-178. https://doi.org/10.1097/01.mcp.0000219265.50310.9b
  16. Raviglione MC. The TB epidemic from 1992 to 2002. Tuberculosis. 2003. 83: 4-14. https://doi.org/10.1016/S1472-9792(02)00071-9
  17. Ruiz M, Torres MJ, Llanos AC, Arroyo A, Palomares JC, Aznar J. Direct detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis in auramine-rhodamine-positive sputum specimens by real-time PCR. J Clin Microbiol. 2004. 42: 1585-1589. https://doi.org/10.1128/JCM.42.4.1585-1589.2004
  18. Russell DG. Mycobacterium tuberculosis: here today and here tomorrow. Nat Rev Mol Cell Biol. 2001. 2: 569-577. https://doi.org/10.1038/35085034
  19. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006. 81: 430-432.
  20. World Health Organization. Global tuberculosis report 2016. World Health Organization Document. 2016.
  21. World Health Organization. Anti-tuberculosis drug resistance in the world. World Health Organization Document. 2008.